Form 6-K Filing: AstraZeneca PLC - Director Shareholding Update

This report details a transaction by Pascal Soriot, Executive Director and CEO of AstraZeneca PLC, on May 14, 2026. An award of ordinary shares, initially granted on March 5, 2021, under the AstraZeneca Performance Share Plan (AZPSP), vested at 88% after a three-year performance period and a subsequent two-year holding period. Following dividend reinvestment and tax withholdings, Mr. Soriot acquired 18,359 ordinary shares for nil consideration. The fair market value of each share at vesting was recorded as 13,766 pence. This notification is made in accordance with the EU Market Abuse Regulation as part of UK law.